tiprankstipranks
Trending News
More News >
Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
US Market
Advertisement

Biodexa Pharmaceuticals (BDRX) Drug Pipeline

Compare
519 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Erapa (Encapsulated Rapamycin)
Familial Adenomatous Polyposis (Fap)
Phase III
Recruiting
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Apr 10, 2025
Mtx110, Programmable Pump And Catheter System
Recurrent Glioblastoma
Phase I
Terminated
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
Mar 28, 2022
Encapsulated Rapamycin (Erapa)
Familial Adenomatous Polyposis
Phase II
Active Not Recruiting
Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Jan 12, 2020

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Biodexa Pharmaceuticals (BDRX) have in its pipeline
      BDRX is currently developing the following drugs: Erapa (Encapsulated Rapamycin), Mtx110, Programmable Pump And Catheter System, Encapsulated Rapamycin (Erapa). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis